Slide 1: ASCRS Analyst Briefing
Exhibit 99.1 ASCRS Analyst Briefing April 4, 2009
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation, made on April 4, 2009, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and ar
Slide 3: Agenda
Agenda Opening Remarks Kevin Buehler ASCRS Key Product Review Bill Barton AcrySof® ReSTOR® +3.0 add AcrySof® IQ Toric AcrySof® Phakic WaveLight® Allegretto Wave® Eye-Q Questions and Answer Session Kevin Buehler Bill Barton Rick Croarkin Sabri Markabi, M.D.
Slide 4: Operating Environment and Outlook
Operating Environment and Outlook Near term continues to be challenging – Economic weakness – Currency headwind – TobraDex generic competition Long-term outlook remains solidly positive – Aging demographics – Emerging market opportunity – Acute and serious chronic disease treatments – Unmet medical
Slide 5: Managing for Future Growth in Challenging Environment
Managing for Future Growth in Challenging Environment Maintain commercial focus and leadership position in eye care Manage discretionary spending consistent with organic growth Capitalize on previous sales force expansions and prioritize spending on demand creation Achieve solid share performance wi
Slide 6: ASCRS Key Product Review
ASCRS Key Product Review Bill Barton Senior Vice President, International Markets
Slide 7: Advanced Technology IOLs are a Key Driver of Growth
Advanced Technology IOLs are a Key Driver of Growth Develop new IOL products to provide better patient outcomes Promote higher value products through clinical differentiation AcrySof® ReSTOR® +3.0 Expand existing brands to give doctors flexibility Enable better worldwide access and patient reimburse
Slide 8: Advanced Technology Sales Trend
Advanced Technology Sales Trend $60 $51.6 $50 $40 (dollars in millions) $30 $20 $10 $- Q1 05 Q2 05 Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 Q4 08 ReSTOR® ReSTOR® CMS Toric Toric CMS ReSTOR® ReSTOR® +3.0 Launch Decision Launch Decision Aspheric Launch Aspheric Lau
Slide 9: AcrySof ReSTOR +3.0
AcrySof ® ReSTOR® +3.0 Aspheric acrylic design based on gold standard AcrySof® material Implanted in over 42 million eyes Excellent posterior capsule opacification (PCO) profile Improves visual performance Extends reading distance Improves intermediate visual acuity AcrySof® ReSTOR® +3.0 Aspheric op
Slide 10: AcrySof ReSTOR IOL in "Human" Terms
AcrySof® ReSTOR® IOL in “Human” Terms Thickness of a human hair = 60 microns Thickness of a red blood cell = 7 microns Step height at periphery of the diffractive portion of the AcrySof ® ReSTOR® Aspheric IOL = 0.2 microns
Slide 11: Competitive Review
Competitive Review ReSTOR® Crystalens HD* ReZoom* Tecnis MF* Aspheric +3.0 Manufacturer Alcon B&L AMO AMO Apodized Optics Accommodative Zonal Refractive Full Optic Diffractive Diffractive Aspheric UV-absorbing & blue Clear acrylic with a Clear acrylic with a Silicone elastomer limited Material light
Slide 12: Substantial Improvement in Intermediate Vision
Substantial Improvement in Intermediate Vision Bilateral Defocus Curve Refraction (D) 1 0.5 0 0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4 -0.1 0 20/20 0.1 20/25 logMAR 0.2 20/32 70 cm (28 in) 0.3 20/40 50 cm (16 in) 60 cm (20 in) 0.4 20/50 0.5 20/63 ReSTOR® Aspheric +3.0 ReSTOR® Aspheric +4.0 Europe Study Data o
Slide 13: Confirmed Visual Acuity in OUS Post Launch Markets
Confirmed Visual Acuity in OUS Post Launch Markets ReSTOR® +3.0 Bilateral UCVA at 6 months Postoperative -0.05 Distance 70cm 60cm 50cm 40cm (near) 0 20/20 0.05 logMAR 0.1 20/25 0.15 0.2 20/32 0.25 N=93 Europe South America Data on File. Alcon, Inc.
Slide 14: Visual Acuity Comparison of the ReSTOR Lenses
Visual Acuity Comparison of the ReSTOR® Lenses Improved Vision at All Distances ReSTOR® Aspheric ReSTOR® Aspheric +3.0 +4.0 20/20 or Better 31.2% 8.4% 20/25 or Better 61.6% 21.4% 20/32 or Better 86.2% 49.6% 20/40 or Better 94.9% 71.8% Worse than 20/40 5.1% 28.2% Note: Comparison of AcrySof® ReSTOR®
Slide 15: AcrySof ReSTOR +3.0 Impacts
AcrySof® ReSTOR® +3.0 Impacts
Slide 16: Alcon at ASCRS: AcrySof ReSTOR +3.0
Alcon at ASCRS: AcrySof® ReSTOR® +3.0 Intermediate Vision with the ReSTOR® +3.0 Aspherical Multifocal IOL – Saturday, 4/4, 3:47-3:52 p.m., Moscone Center, Room 123 – Rudy M. Nuijts, M.D., Netherlands Functional Outcomes of +3.0 D Add Aspheric Multifocal IOL and +4.0 D Add Aspheric Multifocal IOL – M
Slide 17: AcrySof IQ Toric
AcrySof® IQ Toric Aspheric acrylic design based on gold standard AcrySof® material Excellent rotational stability allows for precise astigmatic correction Toric calculator allows for accurate surgical planning Aspheric optic improves image quality and increases contrast sensitivity High rate of pati
Slide 18: What does an Astigmatism look like?
What does an Astigmatism look like? No astigmatism 1.0 D astigmatism 2.0 D astigmatism
Slide 19: AcrySof IQ Technology Improves Contrast Sensitivity
AcrySof® IQ Technology Improves Contrast Sensitivity The aspheric design of AcrySof® IQ IOL offers improved contrast sensitivity resulting in for improved image quality MTF Values 5 mm Aperture. Å Data for the SN6AT5, with cylinder power of › 3.0 D at IOL plane › 2.1 D at corneal plane Data on File.
Slide 20: Improved Uncorrected Distance Visual Acuity
Improved Uncorrected Distance Visual Acuity 94% of patients implanted achieved uncorrected distance visual acuity of 20/40 or better †† AcrySof® Single-Piece (SA60AT) Data on File. Alcon, Inc.
Slide 21: Benefits of Adding AcrySof IQ to AcrySof Toric Lenses
Benefits of Adding AcrySof® IQ to AcrySof® Toric Lenses Patients were tested monocularly in a night driving simulator in simulated city and rural settings under normal, glare and fog conditions. Patients with AcrySof® IQ IOL performed functionally better than the control lens in 34 of 36 conditions
Slide 22: Solid U.S. Surgeon Adoption of AcrySof Toric
Solid U.S. Surgeon Adoption of AcrySof® Toric Percentage of Surgeons using Toric IOLs by Brand 50 46.4% 45 40 35 30.6% As a percent 30 25 20 15 10 5 2.2% 2.0% 0 Q4 2007 Q1 2008 Q2 2008 Q3 2008 Q4 2008 AcrySof® Toric Staar Toric Source: Quarterly Market Scope Cataract Survey
Slide 23: Alcon at ASCRS: AcrySof IQ Toric
Alcon at ASCRS: AcrySof® IQ Toric Rotational Stability of a Toric Hydrophobic Acrylic IOL After Cataract Surgery – Sunday, 4/5, 3:17-3:22 p.m., Moscone Center, Room 120 – Oliver Findl, M.D., Austria Application of the AcrySof Toric IOL in a Patient Population with Low Preoperative Astigmatism (0.75
Slide 24: AcrySof Phakic
AcrySof® Phakic Lens Attributes Unique design and proven AcrySof® material Potential expansion to lower diopter Small incision delivery with minimal endothelial cell loss Effective visual correction supported by clinical results Refractive power range of -6.0 to -16.5 AcrySof® Phakic Low haptic forc
Slide 25: AcrySof Phakic Lens Placement
AcrySof® Phakic Lens Placement Optic Bridge Footplate Iris Crystalline Lens Anterior Chamber Ocular Coherence Tomography US Status: Investigational device limited by Federal Law to investigational use only. *ZEISS is a registered trademarks of Carl Zeiss AG
Slide 26: AcrySof Phakic Lens Placement
AcrySof® Phakic Lens Placement
Slide 27: Degrees of Myopic Vision on the Standard Eye Chart
Degrees of Myopic Vision on the Standard Eye Chart Normal Vision 5 D Myopia Note: Photos above utilize simulated vision 11 D Myopia
Slide 28: What Does a Myopic Patient Actually See?
What Does a Myopic Patient Actually See? Normal Vision Myopic Vision (Approximately -5 D) Note: Photos above utilize simulated vision
Slide 29: AcrySof Phakic Lens Effects on Visual Acuity
AcrySof® Phakic Lens Effects on Visual Acuity Uncorrected Visual Acuity for all Patients at 1 year 97.3% 100% 93.1% 85.0% 80% Percentage of Subjects 65.6% 60% 40% 20% 0% 20/20 or better 20/25 or better 20/30 or better 20/40 or better Cumulative US Status: Investigational device limited by Federal La
Slide 30: Alcon at ASCRS: AcrySof Phakic
Alcon at ASCRS: AcrySof® Phakic AcrySof® Phakic Angle-Supported IOL in U.S. Investigational Trial – Tuesday, 4/7, 8:02-8:07 a.m., Moscone Center, Room 121 – W. Maxwell, M.D., Fresno European Clinical Experience with the AcrySof® Phakic IOL for Moderate to High Myopia – Tuesday, 4/7, 8:12-8:17 a.m.,
Slide 31: WaveLight Allegretto Wave Eye-Q 400Hz Excimer Laser
WaveLight® Allegretto Wave® Eye-Q 400Hz Excimer Laser Most recent approved laser by the FDA, with the broadest approved treatment range Highest rate of 20/20 vision and lowest re-treatment rate in submitted FDA trials Every treatment is personalized to the patient’s individual refraction and c
Slide 32: WaveLight Allegretto Wave Eye-Q 400Hz Excimer Laser
WaveLight® Allegretto Wave® Eye-Q 400Hz Excimer Laser Fastest FDA approved excimer laser Treatment times under 10 seconds Improves patient comfort, reduces anxiety Enhances clinical outcomes WaveLight® Allegretto Increases efficiency Wave® Eye-Q
Slide 33: Competitive Performance
Competitive Performance Alcon/WaveLight has gained 2 procedure share points in 2008 U.S. Procedure Share U.S. Procedure Share as of Q4 2007 as of Q4 2008 24% 26% 61% 62% 14% 10% 1% 2% AMO Alcon/WaveLight B&L Nidek Source: Quarterly Market Scope Refractive Surgeon Survey
Slide 34: Laser Vision Correction Franchise Goals
Laser Vision Correction Franchise Goals Grow refractive laser procedure share through physician preference and patient satisfaction – LCA Vision contract Continue technology leadership Develop the next generation of technology to maintain leadership – Individualized procedures for each patient – Int
Slide 35: UltraFlap Workstation
UltraFlap Workstatsion Preview at: Alcon Booth 1526/1512 WaveLight Booth 1602
Slide 36: Alcon at ASCRS: Refractive Topics
Alcon at ASCRS: Refractive Topics Controversies in Refractive Surgery – Monday, 4/6, 1:00-2:30 p.m., Moscone Center, Room 305 – Karl G. Stonecipher, M.D., Greensboro Ways to Correct Presbyopia: New Strategies and Early Results – Monday, 4/6, 8:00-9:30 a.m., Moscone Center, Room 308 – R. Pinelli, M.D
Slide 37: ASCRS Analyst Briefing
ASCRS Analyst Briefing April 4, 2009